2. Search Result
Search Result
Results for "

metastatic pancreatic adenocarcinoma

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148808
    Zelasudil

    RXC007

    		 ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
    Zelasudil
  • HY-P9974
    Vantictumab
    1 Publications Verification

    OMP-18R5

    		 Wnt Cancer
    Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
    Vantictumab
  • HY-P99049
    Sotigalimab

    APX005M; APX005M; EPI-0050

    		 TNF Receptor Inflammation/Immunology
    Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
    Sotigalimab
  • HY-170859
    AH078

    		PROTACs Casein Kinase Cancer
    AH078 is a PROTAC-based CK1δ/ε degrader (DC50=0.55 μM, Dmax=70%) that lacks subtype selectivity between CK1δ and CK1ε. AH078 induces target protein degradation either by recruiting the CUL4-CRBN E3 ligase complex and proteasome, or via the VHL- and ubiquitin-dependent pathway. AH078 also exhibits selectivity for CK1α, and is widely applicable to research related to colon cancer, pancreatic cancer, breast cancer, ovarian cancer, chronic lymphocytic leukemia, acute myeloid leukemia, glioma, and metastatic breast adenocarcinoma .
    AH078
  • HY-116212
    JCP-170

    		MAGL Cancer
    JCP-170, a substituted chloroisocoumarin, is an ABHD6 inhibitor. JCP-170 robustly and reproducibly inhibits metastatic seeding of the murine cell line 0688M and both human pancreatic ductal adenocarcinoma (PDAC) cell lines .
    JCP-170
  • HY-156184
    Octanoylcarnitine

    		Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Octanoylcarnitine is an orally active medium-chain acylcarnitine transport intermediate in fatty acid β-oxidation. Octanoylcarnitine is converted to octanoyl-CoA by carnitine acetyltransferase (CrAT), which then generates energy via β-oxidation in mitochondria of the heart and skeletal muscle. Octanoylcarnitine enhances grip strength and treadmill endurance, alleviates lactic acidosis, distributes in muscle and heart tissues, increases free carnitine levels, and mitigates mitochondrial stress. Octanoylcarnitine is associated with long-chain fatty acid metabolism, shows a positive correlation with subcutaneous fat area in patients with metastatic pancreatic ductal adenocarcinoma, and is closely related to central retinal artery occlusion (CRAO) .
    Octanoylcarnitine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: